Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Publisher's Note
Right arrow Erratum (v25,p1154)
Right arrow Erratum (v18,p2644)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bubley, G. J.
Right arrow Articles by Wilding, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bubley, G. J.
Right arrow Articles by Wilding, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 17, Issue 11 (November), 1999: 3461-3467
© 1999 American Society for Clinical Oncology

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael Carducci, William Dahut, Nancy Dawson, Danai Daliani, Mario Eisenberger, William D. Figg, Boris Freidlin, Susan Halabi, Gary Hudes, Maha Hussain, Richard Kaplan, Charles Myers, William Oh, Daniel P. Petrylak, Eddie Reed, Bruce Roth, Oliver Sartor, Howard Scher, Jonathan Simons, Vickie Sinibaldi, Eric J. Small, Matthew R. Smith, Donald L. Trump, Robin Vollmer, George Wilding

From the Beth Israel Deaconess Medical CenterDana Farber Cancer Center, and Massachusetts General Hospital, Boston, MA; Johns Hopkins University, Baltimore, MD, National Cancer Institute, Bethesda, MD, University of Maryland, Baltimore, MD, MD Anderson Cancer Center, Houston, TX, Duke University, Durham, NC, Fox Chase Cancer Center, Philadelphia, PA, Wayne State University, Detroit, MI, University of Virginia, Charlottesville, VA, Columbia University, New York, NY, Vanderbilt University, Louisiana State Medical Center, New Orleans, LA, Memorial Sloan Kettering Cancer Center, New York, NY, University of California at San Francisco, San Francisco, CA, Massachusetts General Hospital, Boston, MA, University of Pittsburgh, Pittsburgh, PA, and University of Wisconsin, Madison, WI.

Address reprint requests to William D. Figg, PharmD, Bldg 10, Room 5A01, Medicine Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892; email wdfigg{at}helix.nih.gov

PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA will often antedate changes in bone scan. Furthermore, many but not all investigators have observed an association between a decline in PSA levels of 50% or greater and survival. Since the majority of phase II clinical trials for patients with androgen-independent prostate cancer (AIPC) have used PSA as a marker, we believed it was important for investigators to agree on definitions and values for a minimum set of parameters for eligibility and PSA declines and to develop a common approach to outcome analysis and reporting. We held a consensus conference with 26 leading investigators in the field of AIPC to define these parameters.

RESULT: We defined four patient groups: (1) progressive measurable disease, (2) progressive bone metastasis, (3) stable metastases and a rising PSA, and (4) rising PSA and no other evidence of metastatic disease. The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials. We propose that investigators report at a minimum a PSA decline of at least 50% and this must be confirmed by a second PSA value 4 or more weeks later. Patients may not demonstrate clinical or radiographic evidence of disease progression during this time period. Some investigators may want to report additional measures of PSA changes (ie, 75% decline, 90% decline). Response duration and the time to PSA progression may also be important clinical end point.

CONCLUSION: Through this consensus conference, we believe we have developed practical guidelines for using PSA as a measurement of outcome. Furthermore, the use of common standards is important as we determine which agents should progress to randomized trials which will use survival as an end point.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
N. M. Hahn, R. T. Zon, M. Yu, F. O. Ademuyiwa, T. Jones, W. Dugan, C. Whalen, R. Shanmugam, T. Skaar, and C. J. Sweeney
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
Ann. Onc., December 1, 2009; 20(12): 1971 - 1976.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Khasraw, N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, F. Parnis, V. Lim, R. Harvie, et al.
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Ann. Onc., November 16, 2009; (2009) mdp524v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-E. Taplin, M. M. Regan, Y.-J. Ko, G. J. Bubley, S. E. Duggan, L. Werner, T. M. Beer, C. W. Ryan, P. Mathew, S.-M. Tu, et al.
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
Clin. Cancer Res., November 15, 2009; 15(22): 7099 - 7105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. N. Sternberg, D. P. Petrylak, O. Sartor, J. A. Witjes, T. Demkow, J.-M. Ferrero, J.-C. Eymard, S. Falcon, F. Calabro, N. James, et al.
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
J. Clin. Oncol., November 10, 2009; 27(32): 5431 - 5438.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. McNeel, E. J. Dunphy, J. G. Davies, T. P. Frye, L. E. Johnson, M. J. Staab, D. L. Horvath, J. Straus, D. Alberti, R. Marnocha, et al.
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
J. Clin. Oncol., September 1, 2009; 27(25): 4047 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Attard, A. H.M. Reid, R. A'Hern, C. Parker, N. B. Oommen, E. Folkerd, C. Messiou, L. R. Molife, G. Maier, E. Thompson, et al.
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
J. Clin. Oncol., August 10, 2009; 27(23): 3742 - 3748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, et al.
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Clin. Cancer Res., August 1, 2009; 15(15): 4954 - 4962.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. J. Armstrong and P. G. Febbo
Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature
Oncologist, August 1, 2009; 14(8): 816 - 827.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. M. Regan, E. K. O'Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, and W. K. Oh
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
Ann. Onc., July 24, 2009; (2009) mdp308v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Michels, S. L. Ellard, L. Le, C. Kollmannsberger, N. Murray, E. S. Tomlinson Guns, R. Carr, and K. N. Chi
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
Ann. Onc., July 24, 2009; (2009) mdp311v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. R. Molife, G. Attard, P. C. Fong, V. Karavasilis, A. H. M. Reid, S. Patterson, C. E. Riggs Jr, C. Higano, W. M. Stadler, W. McCulloch, et al.
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
Ann. Onc., July 16, 2009; (2009) mdp270v1.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. C. Fong, D. S. Boss, T. A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M. J. O'Connor, et al.
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
N. Engl. J. Med., July 9, 2009; 361(2): 123 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, et al.
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
Ann. Onc., July 1, 2009; 20(7): 1264 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. B. Michaud
The Epothilones: How Pharmacology Relates to Clinical Utility
Ann. Pharmacother., July 1, 2009; 43(7): 1294 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Rosenberg, C. J. Ryan, V. K. Weinberg, D. C. Smith, M. Hussain, T. M. Beer, C. W. Ryan, P. Mathew, L. C. Pagliaro, A. L. Harzstark, et al.
Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
J. Clin. Oncol., June 10, 2009; 27(17): 2772 - 2778.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Halabi, N. J. Vogelzang, S.-S. Ou, K. Owzar, L. Archer, and E. J. Small
Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2766 - 2771.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. D. Ricart, J. Sarantopoulos, E. Calvo, Q. S. Chu, D. Greene, F. E. Nathan, M. E. Petrone, A. W. Tolcher, and K. P. Papadopoulos
Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study
Clin. Cancer Res., June 1, 2009; 15(11): 3866 - 3871.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al.
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hussain, B. Goldman, C. Tangen, C. S. Higano, D. P. Petrylak, G. Wilding, A. M. Akdas, E. J. Small, B. J. Donnelly, S. K. Sundram, et al.
Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
J. Clin. Oncol., May 20, 2009; 27(15): 2450 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith
Phase II study of sunitinib in men with advanced prostate cancer
Ann. Onc., May 1, 2009; 20(5): 913 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Attard, J. F. Swennenhuis, D. Olmos, A. H.M. Reid, E. Vickers, R. A'Hern, R. Levink, F. Coumans, J. Moreira, R. Riisnaes, et al.
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Cancer Res., April 1, 2009; 69(7): 2912 - 2918.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Dale, J. Hemmerich, K. Bylow, S. Mohile, M. Mullaney, and W. M. Stadler
Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study
J. Clin. Oncol., April 1, 2009; 27(10): 1557 - 1563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. McShane, S. Hunsberger, and A. A. Adjei
Effective Incorporation of Biomarkers into Phase II Trials
Clin. Cancer Res., March 15, 2009; 15(6): 1898 - 1905.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. S. Azad, J. B. Aragon-Ching, W. L. Dahut, M. Gutierrez, W. D. Figg, L. Jain, S. M. Steinberg, M. L. Turner, E. C. Kohn, and H. H. Kong
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Clin. Cancer Res., February 15, 2009; 15(4): 1411 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Tevaarwerk, K. D. Holen, D. B. Alberti, C. Sidor, J. Arnott, C. Quon, G. Wilding, and G. Liu
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Clin. Cancer Res., February 15, 2009; 15(4): 1460 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
D. PECTASIDES, E. PECTASIDES, G. PAPAXOINIS, A. KOUMARIANOU, A. PSYRRI, N. XIROS, N. TOUNTAS, K. KAMPOSIORAS, G. PAPATSIBAS, T. FLOROS, et al.
Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer: A Single Institution Experience
Anticancer Res, February 1, 2009; 29(2): 769 - 775.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Fong, S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, et al.
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Cancer Res., January 15, 2009; 69(2): 609 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Olmos, H.-T. Arkenau, J. E. Ang, I. Ledaki, G. Attard, C. P. Carden, A. H. M. Reid, R. A'Hern, P. C. Fong, N. B. Oomen, et al.
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
Ann. Onc., January 1, 2009; 20(1): 27 - 33.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. B. Apolo, N. Pandit-Taskar, and M. J. Morris
Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer
J. Nucl. Med., December 1, 2008; 49(12): 2031 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. I. Heath, D. W. Hillman, U. Vaishampayan, S. Sheng, F. Sarkar, F. Harper, M. Gaskins, H. C. Pitot, W. Tan, S. P. Ivy, et al.
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7940 - 7946.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-P. Machiels, F. Mazzeo, M. Clausse, B. Filleul, L. Marcelis, B. Honhon, L. D'Hondt, C. Dopchie, V. Verschaeve, L. Duck, et al.
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
J. Clin. Oncol., November 10, 2008; 26(32): 5261 - 5268.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Attard, A. H.M. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, et al.
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
J. Clin. Oncol., October 1, 2008; 26(28): 4563 - 4571.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Colloca, F. Checcaglini, and A. Venturino
About sorafenib in castration-resistant prostate cancer
Ann. Onc., October 1, 2008; 19(10): 1812 - 1813.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6302 - 6309.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
S. Basaria
Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth
J Androl, September 1, 2008; 29(5): 534 - 539.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Blood, August 15, 2008; 112(4): 1175 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Thuret, C. Massard, M. Gross-Goupil, B. Escudier, M. Di Palma, A. Bossi, R. de Crevoisier, A. Chauchereau, and K. Fizazi
The postchemotherapy PSA surge syndrome
Ann. Onc., July 1, 2008; 19(7): 1308 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Shahani, M. Braga-Basaria, and S. Basaria
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2042 - 2049.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Halabi, N. J. Vogelzang, A. B. Kornblith, S.-S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small
Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer
J. Clin. Oncol., May 20, 2008; 26(15): 2544 - 2549.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. D. Galsky, M. Eisenberger, S. Moore-Cooper, W. K. Kelly, S. F. Slovin, A. DeLaCruz, Y. Lee, I. J. Webb, and H. I. Scher
Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
J. Clin. Oncol., May 1, 2008; 26(13): 2147 - 2154.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, et al.
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Clin. Cancer Res., April 15, 2008; 14(8): 2437 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. N. Chi, S. L. Ellard, S. J. Hotte, P. Czaykowski, M. Moore, J. D. Ruether, A. J. Schell, S. Taylor, C. Hansen, I. Gauthier, et al.
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
Ann. Onc., April 1, 2008; 19(4): 746 - 751.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, et al.
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
J. Clin. Oncol., March 1, 2008; 26(7): 1148 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang
Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. N. Chi, L. L. Siu, H. Hirte, S. J. Hotte, J. Knox, C. Kollmansberger, M. Gleave, E. Guns, J. Powers, W. Walsh, et al.
A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
Clin. Cancer Res., February 1, 2008; 14(3): 833 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Tomioka, M. Shimbo, Y. Amiya, H. Nakatsu, S. Murakami, and J. Shimazaki
Outcome of Patients with Hormone-Refractory Prostate Cancer: Prognostic Significance of Prostate-Specific Antigen-Doubling Time and Nadir Prostate-Specific Antigen
Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 36 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. L. Dahut, C. Scripture, E. Posadas, L. Jain, J. L. Gulley, P. M. Arlen, J. J. Wright, Y. Yu, L. Cao, S. M. Steinberg, et al.
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, et al.
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Clin. Cancer Res., December 1, 2007; 13(23): 7053 - 7058.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. F. Thall, C. Logothetis, L. C. Pagliaro, S. Wen, M. A. Brown, D. Williams, and R. E. Millikan
Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens
J Natl Cancer Inst, November 7, 2007; 99(21): 1613 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Oudard, E. Banu, F. Scotte, A. Banu, J. Medioni, P. Beuzeboc, F. Joly, J.-M. Ferrero, F. Goldwasser, and J.-M. Andrieu
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
Ann. Onc., November 1, 2007; 18(11): 1828 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Armstrong, E. Garrett-Mayer, Y.-C. Ou Yang, M. A. Carducci, I. Tannock, R. de Wit, and M. Eisenberger
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3965 - 3970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Small, N. Sacks, J. Nemunaitis, W. J. Urba, E. Dula, A. S. Centeno, W. G. Nelson, D. Ando, C. Howard, F. Borellini, et al.
Granulocyte Macrophage Colony-Stimulating Factor-Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer
Clin. Cancer Res., July 1, 2007; 13(13): 3883 - 3891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. de Bono, G. Attard, A. Adjei, M. N. Pollak, P. C. Fong, P. Haluska, L. Roberts, C. Melvin, M. Repollet, D. Chianese, et al.
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
Clin. Cancer Res., June 15, 2007; 13(12): 3611 - 3616.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J-C Eymard, F Priou, A Zannetti, A Ravaud, D Lepille, P Kerbrat, P Gomez, B Paule, D Genet, P Herait, et al.
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
Ann. Onc., June 1, 2007; 18(6): 1064 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, and J. P. Allison
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1810 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. I. Scher, M. Warren, and G. Heller
The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer
Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Beer, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. S. Chatta, J. D. Ruether, C. H. Redfern, L. Fehrenbacher, M. N. Saleh, D. M. Waterhouse, et al.
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators
J. Clin. Oncol., February 20, 2007; 25(6): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. B. Agus, C. J. Sweeney, M. J. Morris, D. S. Mendelson, D. G. McNeel, F. R. Ahmann, J. Wang, M. K. Derynck, K. Ng, B. Lyons, et al.
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
J. Clin. Oncol., February 20, 2007; 25(6): 675 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. O'Mahony, J. C. Morris, C. Quinn, W. Gao, W. H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T. A. Fleisher, et al.
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
Clin. Cancer Res., February 1, 2007; 13(3): 958 - 964.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al.
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. M. Hahn, S. Marsh, W. Fisher, R. Langdon, R. Zon, M. Browning, C. S. Johnson, T. J. Scott-Horton, L. Li, H. L. McLeod, et al.
Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis.
Clin. Cancer Res., October 15, 2006; 12(20): 6094 - 6099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yoshino, H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno, and M. Igawa
Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Clin. Cancer Res., October 15, 2006; 12(20): 6116 - 6124.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, et al.
Interleukin 6, a Nuclear Factor-{kappa}B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-{kappa}B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity.
Clin. Cancer Res., September 15, 2006; 12(18): 5578 - 5586.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. J. Small, P. F. Schellhammer, C. S. Higano, C. H. Redfern, J. J. Nemunaitis, F. H. Valone, S. S. Verjee, L. A. Jones, and R. M. Hershberg
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
J. Clin. Oncol., July 1, 2006; 24(19): 3089 - 3094.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Smith, J. Manola, D. S. Kaufman, W. K. Oh, G. J. Bubley, and P. W. Kantoff
Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy
J. Clin. Oncol., June 20, 2006; 24(18): 2723 - 2728.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Simons, M. A. Carducci, B. Mikhak, M. Lim, B. Biedrzycki, F. Borellini, S. M. Clift, K. M. Hege, D. G. Ando, S. Piantadosi, et al.
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naive Prostate Cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3394 - 3401.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Beer, M. Garzotto, B. Park, M. Mori, A. Myrthue, N. Janeba, D. Sauer, and K. Eilers
Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans.
Clin. Cancer Res., May 1, 2006; 12(9): 2812 - 2816.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. P. Tarassoff, P. M. Arlen, and J. L. Gulley
Therapeutic vaccines for prostate cancer.
Oncologist, May 1, 2006; 11(5): 451 - 462.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. P. Petrylak, D. P. Ankerst, C. S. Jiang, C. M. Tangen, M. H. A. Hussain, P. N. Lara Jr., J. A. Jones, M. E. Taplin, P. A. Burch, M. Kohli, et al.
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
J Natl Cancer Inst, April 19, 2006; 98(8): 516 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Lara Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, et al.
A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Clin. Cancer Res., March 1, 2006; 12(5): 1556 - 1563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, D. Panicali, P. Beetham, K. Y. Tsang, D. W. Grosenbach, J. Feldman, et al.
A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1260 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hussain, C. M. Tangen, P. N. Lara Jr, U. N. Vaishampayan, D. P. Petrylak, A. D. Colevas, W. A. Sakr, and E. D. Crawford
Ixabepilone (Epothilone B Analogue BMS-247550) Is Active in Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer: A Southwest Oncology Group Trial S0111
J. Clin. Oncol., December 1, 2005; 23(34): 8724 - 8729.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. W. Ross, S. Halabi, S.-S. Ou, B. R. Rajeshkumar, B. A. Woda, N. J. Vogelzang, E. J. Small, M.-E. Taplin, and P. W. Kantoff
Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer--A Cancer and Leukemia Group B Study
Clin. Cancer Res., November 15, 2005; 11(22): 8109 - 8113.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. M. Stadler, L. C. Michaelis, and M. J. Ratain
Randomized Phase II Trials and Prostate-Specific Antigen Endpoints in Prostate Cancer: Much Ado About Nothing?
J. Clin. Oncol., November 1, 2005; 23(31): 8124 - 8125.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Sweeney, G. Liu, C. Yiannoutsos, J. Kolesar, D. Horvath, M. J. Staab, K. Fife, V. Armstrong, A. Treston, C. Sidor, et al.
A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6625 - 6633.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. W. Ross, J. Manola, K. Hennessy, M. Galsky, H. Scher, E. Small, W. K. Kelly, and P. W. Kantoff
Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy
Clin. Cancer Res., July 15, 2005; 11(14): 5195 - 5198.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller
Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards
Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. G. Febbo, J. P. Richie, D. J. George, M. Loda, J. Manola, S. Shankar, A. Szot Barnes, C. Tempany, W. Catalona, P. W. Kantoff, et al.
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5233 - 5240.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. Sharifi, J. L. Gulley, and W. L. Dahut
Androgen Deprivation Therapy for Prostate Cancer
JAMA, July 13, 2005; 294(2): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Oudard, E. Banu, P. Beuzeboc, E. Voog, L. M. Dourthe, A. C. Hardy-Bessard, C. Linassier, F. Scotte, A. Banu, Y. Coscas, et al.
Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3343 - 3351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hussain, N. Dawson, P. Amin, C. Engstrom, B. Dorsey, E. Siegel, and C. Guo
Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer
J. Clin. Oncol., April 20, 2005; 23(12): 2789 - 2796.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. D. Galsky, E. J. Small, W. K. Oh, I. Chen, D. C. Smith, A. D. Colevas, L. Martone, T. Curley, A. DeLaCruz, H. I. Scher, et al.
Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer
J. Clin. Oncol., March 1, 2005; 23(7): 1439 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Font, A. Murias, F. R. Garcia Arroyo, C. Martin, J. Areal, J. J. Sanchez, J. A. Santiago, M. Constenla, J. M. Saladie, and R. Rosell
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
Ann. Onc., March 1, 2005; 16(3): 419 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Rademaker-Lakhai, S. Horenblas, W. Meinhardt, E. Stokvis, T. M. de Reijke, J. M. Jimeno, L. Lopez-Lazaro, J. A. Lopez Martin, J. H. Beijnen, and J. H.M. Schellens
Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 1854 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.M. Canil, M.J. Moore, E. Winquist, T. Baetz, M. Pollak, K.N. Chi, S. Berry, D.S. Ernst, L. Douglas, M. Brundage, et al.
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
J. Clin. Oncol., January 20, 2005; 23(3): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. K. Oh, E. Hagmann, J. Manola, D. J. George, T. D. Gilligan, J. O. Jacobson, M. R. Smith, D. S. Kaufman, and P. W. Kantoff
A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., January 1, 2005; 11(1): 284 - 289.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. G. Roberts Jr, B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, and J. W. Clark
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
JAMA, November 3, 2004; 292(17): 2130 - 2140.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online